CN1753906A - 培哚普利和其可药用盐的新合成方法 - Google Patents
培哚普利和其可药用盐的新合成方法 Download PDFInfo
- Publication number
- CN1753906A CN1753906A CNA2004800054059A CN200480005405A CN1753906A CN 1753906 A CN1753906 A CN 1753906A CN A2004800054059 A CNA2004800054059 A CN A2004800054059A CN 200480005405 A CN200480005405 A CN 200480005405A CN 1753906 A CN1753906 A CN 1753906A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- perindopril
- mole
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明涉及式(I)的培哚普利和其可药用盐的合成方法。
Description
本发明涉及式(I)的培哚普利和其可药用盐的合成方法:
培哚普利和其可药用盐、尤其是其叔丁基胺盐具有有价值的药理学性质。
它们的主要性质是对血管紧张素I转化酶(或激肽酶II)具有抑制作用,该作用一方面可以阻止十肽的血管紧张素I转化成八肽的血管紧张素II(一种血管收缩剂),另一方面可以阻止缓激肽(一种血管舒张剂)降解成无活性的肽。
这两种作用使得培哚普利在心血管疾病中、尤其是在高血压和心力衰竭中具有有益的作用。
培哚普利、其制备方法以及在治疗中的应用描述于欧洲专利说明书EP 0 049 658。
考虑到该化合物的药理学价值,最重要的是能够通过有效的合成方法获得这种化合物,所述方法易于转化到工业化规模,能够以良好的收率和优异的纯度得到培哚普利,并且原料价格合理。
EP 0 308 341描述了工业化合成培哚普利的方法,该方法包括使(2S,3aS,7aS)-八氢吲哚-2-甲酸苄基酯与N-[(S)-1-羧基丁基]-(S)-丙氨酸乙酯反应,再通过催化氢化将杂环的羧酸基团脱保护。
但是,(2S,3aS,7aS)-八氢吲哚-2-甲酸酯不能购买到,并且其制备过程需要采用以吲哚-2-甲酸为原料的多步合成步骤(包括拆分步骤)。
本申请人现已开发出了由易于获得的原料合成培哚普利的新方法。
更具体地说,本发明涉及培哚普利和其可药用盐的工业化合成方法,其特征在于,使式(II)的1-(1-环己烯-1-基)-吡咯烷:
与式(III)的化合物反应:
其中,R1表示酸官能团保护基团,R2表示胺官能团的保护基团,得到式(IV)的化合物:
其中,R1和R2如前定义,
在进行环化前对胺官能团进行脱保护,再进行脱水,得到式(V)的化合物:
其中R1如前定义,
或其与无机或有机酸的加成盐,
将其与式(VI)的化合物在乙酸乙酯中、在20至77℃的温度下反应:
反应在1-羟基苯并三唑和二环己基碳二亚胺存在下进行,以每摩尔所采用的式(V)化合物的量计,1-羟基苯并三唑的量为0.4-0.6摩尔,二环己基碳二亚胺的量为1-1.2摩尔,
反应在三乙胺存在下进行,以每摩尔所采用的式(V)化合物的量计,三乙胺的量为0.25-1.2摩尔,
在分离后得到式(VII)的化合物:
其中,R1如前定义,
将其在催化剂例如钯、铂、铑或镍的存在下、在1-30巴,优选1-10巴的氢气压力下进行氢化,在对酸官能团脱保护后,得到式(I)的培哚普利,如果需要的话,可将其转化成可药用盐如叔丁基胺盐。
以下实施例用于说明本发明,但并非对本发明的限制。
实施例:(2S,3aS,7aS)-1-{(2S)-2-[(1S)-1-(乙氧羰基)-丁基氨基]-丙酰基}-八氢-1H-吲哚-2-甲酸叔丁基胺盐
步骤A:(2S)-2-[(叔丁氧羰基)-氨基]-3-(2-氧代环己基)-丙酸苄酯
在备有回流柱的反应器中,加入200g 1-(1-环己烯-1-基)-吡咯烷、535g(2S)-2-[(叔丁氧羰基)-氨基]-3-碘丙酸苄酯和1.5L乙腈。
回流1小时,然后将混合物恢复至室温。蒸出溶剂后,加入2L水,再加入乙酸。用乙酸乙酯萃取,蒸发至干。
以此方式获得(2S)-2-[(叔丁氧羰基)-氨基]-3-(2-氧代环己基)-丙酸苄酯,收率为80%。
步骤B:(2S)-2-氨基-3-(2-氧代环己基)-丙酸苄酯
在反应器中,加入200g前一步骤获得的化合物、1,5L二氯甲烷和60g三氟乙酸。在室温下搅拌1小时30分钟后,加入2L饱和碳酸氢钠溶液。用二氯甲烷萃取并蒸发至干。
以此方式获得(2S)-2-氨基-3-(2-氧代环己基)-丙酸苄酯,收率为90%。
步骤C:(2S)-2,3,4,5,6,7-六氢-1H-吲哚-2-甲酸苄酯对甲苯磺酸盐
在反应器中,回流200g前一步骤获得的化合物、151.9g对甲苯磺酸和1L甲苯,通过共沸蒸馏除去形成的水。当不再分离出水时,蒸出甲苯。
以此方式获得(2S)-2,3,4,5,6,7-六氢-1H-吲哚-2-甲酸苄酯对甲苯磺酸盐,粗品收率为97%。
步骤D:(2S)-1-{(2S)-2-[(1S)-1-(乙氧羰基)-丁基氨基]-丙酰基}-2,3,4,5,6,7-六氢-1H-吲哚-2-甲酸苄酯
在反应器中,加入200g前一步骤获得的化合物、46g三乙胺和1L乙酸乙酯,在室温下搅拌10分钟后,再加入104g N-[(S)-乙氧羰基-1-丁基]-(S)-丙氨酸、30g 1-羟基苯并三唑和100g二环己基碳二亚胺。然后,在良好搅拌下将多相混合物在30℃下加热3小时,然后冷却至0℃并过滤。再将滤液洗涤并蒸发至干,得到目的产物,收率为95%。
步骤E:(2S,3aS,7aS)-1-{(2S)-2-[(1S)-1-(乙氧羰基)-丁基氨基]-丙酰基-八氢-1H-吲哚-2-甲酸
向氢化反应器中加入溶解于乙酸中的200g前一步骤获得的化合物,然后加入5g 10%Pt/C。在5巴的压力和室温下进行氢化,直至吸收了理论量的氢气。过滤除去催化剂,然后冷却至0-5℃,过滤收集形成的固体。洗涤滤饼,干燥至恒重。以此方式获得(2S,3aS,7aS)-1-{(2S)-2-[(1S)-1-(乙氧羰基)-丁基氨基]-丙酰基}-八氢-1H-吲哚-2-甲酸,收率为85%,对映体纯度为99%。
步骤F:(2S,3aS,7aS)-1-{(2S)-2-[(1S)-1-(乙氧羰基)-丁基氨基]-丙酰基}-八氢-1H-吲哚-2-甲酸叔丁基胺盐
将前一步骤获得的化合物(200g)溶解于2.8L乙酸乙酯,然后加入40g叔丁基胺和0.4L乙酸乙酯。然后,将获得的悬浮液回流,直至完全溶解,再将获得的溶液趁热过滤,搅拌下冷却至15-20℃。然后,滤出获得的沉淀,再次用乙酸乙酯成糊,干燥然后粉碎,得到目的产物,收率为95%。
Claims (4)
1.式(I)的培哚普利和其可药用盐的合成方法,
其特征在于,使式(II)的1-(1-环己烯-1-基)-吡咯烷:
与式(III)的化合物反应:
其中,R1表示酸官能团保护基团,R2表示胺官能团的保护基团,
得到式(IV)的化合物:
其中,R1和R2如前定义,
在进行环化前对胺官能团进行脱保护,再进行脱水,得到式(V)的化合物:
其中R1如前定义,
或其与无机或有机酸的加成盐,
将其与式(VI)的化合物在乙酸乙酯中、在20至77℃的温度下反应:
反应在1-羟基苯并三唑和二环己基碳二亚胺存在下进行,以每摩尔所采用
的式(V)化合物的量计,1-羟基苯并三唑的量为0.4-0.6摩尔,二环己基碳二
亚胺的量为1-1.2摩尔,
反应4在三乙胺存在下进行,以每摩尔所采用的式(V)化合物的量计,三乙
胺的量为0.25-1.2摩尔,
在分离后得到式(VII)的化合物:
其中,R1如前定义,
将其在催化剂的存在下、在1-30巴的氢气压力下进行氢化,在对酸官能团脱保护后,得到式(I)的培哚普利,如果需要的话,可将其转化成可药用盐如叔丁基胺盐。
2.根据权利要求1的合成方法,其特征在于,氢化反应中的氢气压力为1-10巴。
3.根据权利要求1的合成方法,其中,催化剂选自钯、铂、铑和镍。
4.根据权利要求1的方法,用于合成叔丁基胺盐形式的培哚普利。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03290485.6 | 2003-02-28 | ||
EP03290485A EP1403275B1 (fr) | 2003-02-28 | 2003-02-28 | Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1753906A true CN1753906A (zh) | 2006-03-29 |
CN1326871C CN1326871C (zh) | 2007-07-18 |
Family
ID=31970533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004800054059A Expired - Fee Related CN1326871C (zh) | 2003-02-28 | 2004-02-27 | 培哚普利和其可药用盐的新合成方法 |
Country Status (18)
Country | Link |
---|---|
US (1) | US7166633B2 (zh) |
EP (1) | EP1403275B1 (zh) |
JP (1) | JP4563372B2 (zh) |
CN (1) | CN1326871C (zh) |
AR (1) | AR043409A1 (zh) |
AT (1) | ATE307139T1 (zh) |
AU (1) | AU2004217599B2 (zh) |
DE (1) | DE60301930T2 (zh) |
DK (1) | DK1403275T3 (zh) |
EA (1) | EA009066B1 (zh) |
ES (1) | ES2250846T3 (zh) |
HK (1) | HK1086281A1 (zh) |
MY (1) | MY136989A (zh) |
NZ (1) | NZ541424A (zh) |
PL (1) | PL215131B1 (zh) |
SI (1) | SI1403275T1 (zh) |
WO (1) | WO2004078107A2 (zh) |
ZA (1) | ZA200505781B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE307139T1 (de) * | 2003-02-28 | 2005-11-15 | Servier Lab | Verfahren für die synthese von perindopril und seiner pharmazeutisch annehmbaren salze |
US7732621B2 (en) * | 2004-12-28 | 2010-06-08 | Dsm Ip Assets B.V. | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid |
ES2832323T3 (es) | 2013-12-27 | 2021-06-10 | Molten Corp | Pelota |
FR3050380B1 (fr) | 2016-04-20 | 2020-07-10 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ202903A (en) * | 1981-12-29 | 1988-01-08 | Hoechst Ag | 1-- pe pyrrol-2-yl-carboxylic acid derivatives and pharmaceutical compositions |
FR2620709B1 (fr) * | 1987-09-17 | 1990-09-07 | Adir | Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese |
FR2807431B1 (fr) * | 2000-04-06 | 2002-07-19 | Adir | Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables |
FR2827860B1 (fr) * | 2001-07-24 | 2004-12-10 | Servier Lab | Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril |
CN100448675C (zh) * | 2002-02-07 | 2009-01-07 | 株式会社理光 | 喷墨装置、压强调节机构及喷墨打印机 |
ATE307139T1 (de) * | 2003-02-28 | 2005-11-15 | Servier Lab | Verfahren für die synthese von perindopril und seiner pharmazeutisch annehmbaren salze |
-
2003
- 2003-02-28 AT AT03290485T patent/ATE307139T1/de active
- 2003-02-28 SI SI200330102T patent/SI1403275T1/sl unknown
- 2003-02-28 EP EP03290485A patent/EP1403275B1/fr not_active Expired - Lifetime
- 2003-02-28 DE DE60301930T patent/DE60301930T2/de not_active Expired - Lifetime
- 2003-02-28 DK DK03290485T patent/DK1403275T3/da active
- 2003-02-28 ES ES03290485T patent/ES2250846T3/es not_active Expired - Lifetime
-
2004
- 2004-02-27 PL PL377238A patent/PL215131B1/pl unknown
- 2004-02-27 AR ARP040100609A patent/AR043409A1/es not_active Application Discontinuation
- 2004-02-27 MY MYPI20040682A patent/MY136989A/en unknown
- 2004-02-27 NZ NZ541424A patent/NZ541424A/en not_active IP Right Cessation
- 2004-02-27 ZA ZA200505781A patent/ZA200505781B/en unknown
- 2004-02-27 EA EA200501258A patent/EA009066B1/ru not_active IP Right Cessation
- 2004-02-27 JP JP2006500163A patent/JP4563372B2/ja not_active Expired - Fee Related
- 2004-02-27 WO PCT/FR2004/000446 patent/WO2004078107A2/fr active Application Filing
- 2004-02-27 CN CNB2004800054059A patent/CN1326871C/zh not_active Expired - Fee Related
- 2004-02-27 US US10/547,131 patent/US7166633B2/en not_active Expired - Fee Related
- 2004-02-27 AU AU2004217599A patent/AU2004217599B2/en not_active Ceased
-
2006
- 2006-05-29 HK HK06106195A patent/HK1086281A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL215131B1 (pl) | 2013-10-31 |
AR043409A1 (es) | 2005-07-27 |
AU2004217599A1 (en) | 2004-09-16 |
DK1403275T3 (da) | 2005-12-05 |
PL377238A1 (pl) | 2006-01-23 |
EP1403275A1 (fr) | 2004-03-31 |
ES2250846T3 (es) | 2006-04-16 |
DE60301930D1 (de) | 2006-03-02 |
CN1326871C (zh) | 2007-07-18 |
JP4563372B2 (ja) | 2010-10-13 |
MY136989A (en) | 2008-12-31 |
EA009066B1 (ru) | 2007-10-26 |
EA200501258A1 (ru) | 2006-04-28 |
DE60301930T2 (de) | 2006-07-27 |
NZ541424A (en) | 2008-03-28 |
HK1086281A1 (en) | 2006-09-15 |
SI1403275T1 (sl) | 2006-02-28 |
ZA200505781B (en) | 2006-11-29 |
EP1403275B1 (fr) | 2005-10-19 |
US20060149081A1 (en) | 2006-07-06 |
JP2006519177A (ja) | 2006-08-24 |
US7166633B2 (en) | 2007-01-23 |
WO2004078107A2 (fr) | 2004-09-16 |
AU2004217599B2 (en) | 2009-07-30 |
WO2004078107A3 (fr) | 2004-10-21 |
ATE307139T1 (de) | 2005-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0088341B1 (en) | Substituted acyl derivative of octahydro-1h-indole-2-carboxylic acid | |
CN1802384B (zh) | 培哚普利及其可药用盐的新合成方法 | |
CN100383159C (zh) | 培哚普利及其可药用盐的新合成方法 | |
CN1753906A (zh) | 培哚普利和其可药用盐的新合成方法 | |
CN1753907A (zh) | (2S,3aS,7aS)-1-[(S)-丙氨酰]-八氢-1H-吲哚-2-甲酸衍生物的新合成方法及其在合成培哚普利中的应用 | |
US7183308B1 (en) | Metod for the synthesis of perindopril and the pharmaceutically acceptable salts thereof | |
CN100364974C (zh) | (2S,3aS,7aS)-全氢吲哚-2-甲酸和其酯的新合成方法及其在合成培哚普利中的应用 | |
CN1835965A (zh) | 合成培哚普利及其药学可接受盐的新方法 | |
JPH0247480B2 (zh) | ||
WO2005023842A1 (fr) | Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables | |
EA012034B1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
CN1826351A (zh) | 合成培哚普利及其药学可接受盐的新方法 | |
CN1826352A (zh) | 合成培哚普利及其药学可接受盐的新方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1086281 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070718 Termination date: 20190227 |
|
CF01 | Termination of patent right due to non-payment of annual fee |